Expertise
We perfomed trials in the following applications:
| Indication | Phases | Patients up to | Centres up to | Countries up to |
|---|---|---|---|---|
| Allopecia | IIIa | 110 | 1 | 1 |
| Anemia | IIIb, IV, Registry | 400 | 50 | 15 |
| COPD | IV, Registry | 6000 | 300 | 1 |
| Diabetes | IV, Registry | 1250 | 300 | 10 |
| Ferritin deficiency | IV | 200 | 1 | 1 |
| Hepatitis | IV, Registry | 7652 | 460 | 30 |
| Herpes | IV | 300 | 50 | 1 |
| HIV | IV, Registry | 5000 | 500 | 10 |
| Hypertension | IV | 150 | 3 | 1 |
| Nephrology | IV | 240 | 20 | 1 |
| Obesity | IV | 320 | 16 | 1 |
| Oncology | I, II, III, IV, Registry | 400 | 120 | 1 |
| Orthopedics | IV | 120 | 12 | 1 |
| Osteopetrosis | IV | 150 | 10 | 1 |
| Osteoporosis | IV | 70 | 1 | 1 |
| Pain | IIIb | 400 | 50 | 1 |
| PAOD | III, IV | 250 | 17 | 4 |
| Parkinson's Disease | III | 10 | 1 | 1 |
| Prophylaxy, Stop Smoking | IV, Registry | 1300 | 3 | 1 |
| Psychiatry | IV | 200 | 75 | 1 |
| Restless Legs Syndrome | IIIa | 60 | 3 | 1 |
| Transplantation | III, IV, Registry | 2000 | 100 | 25 |
| VPC | III | 35 | 1 | 1 |
| Wound Treatment | IV | 280 | 11 | 1 |
Latest References
F. Barlesi, A. Pazzola, V. Gorbounova, F. Grossi, M. Köhler, J. Mezger, F. Peters, J.M. Trigo, A. Vikstrom, H.J.M. Groen, MAINTENANCE BEVACIZUMAB WITH OR WITHOUT PEMETREXED (PEM) FOLLOWING FIRST-LINE BEVACIZUMAB-CISPLATIN (CIS)-PEM IN PATIENTS (PTS) WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): PRELIMINARY SAFETY DATA FROM AVAPERL1 (MO22089), AVAPERL1 poster to be presented at the ESMO 2010 meeting, Milan, 8/2010.
Geisthövel, F.; A. Wacker; G. Brabant; F. Botsch; A. Maechtel; B. Wetzka; A. Ochsner, Novel Systematics of Nomenclature and Classification of Female Functional Androgenization (Including Polycystic Ovary Syndrome and Non-Classic Congenital Adrenal Hyperplasia), J Reproduktionsmed Endokrinol 2010; 7 (1): 6–26.
Miller, G. G.; Kaplan, B., Prophylaxis versus Preemptive Protocols for CMV: Do They Impact Graft Survival, American Journal of Transplantation, Volume 8, Number 5, May 2008 , pp. 913-914(2), Blackwell Publishing
Knechten, H., Carganico A., Glaessel F., Jaeger H., Knecht G., Koeppe S., Lutz T., Mayr C., Mosthaf F., Schewe K., Schuler C., Stephan C., Wolf E., Steinmueller J., Waesle B., Tappe A., Wellmann E., The rainbow cohort: Saquinavir/r is effective and well tolerated in antiretroviral therapy (ART)-naïve patients initiating treatment with saquinavir 500 mg film-coated tablets - 24 week interim results from Germany, European Journal of Medical Research, Vol. 12, Suppl. II, 80/2007
Degen O., Gläßel F., Knechten H., Köppe S., Moll A., Gute P., Tappe A., Wellmann E., Stellbrink H.-J., Data from the Connecto cohort confirm that Enfuvirtide is effective and well tolerated in treatment experienced patients - 24 weeks interim results from Germany, European Journal of Medical Research, Vol. 12, Suppl. II, 87/2007
Baumgarten A., Hintsche B., Ulmer A., Mayr C., Schmidt W., Pfeil B., Bänsch U., Gorriahn D., Buhk T., Holm S., Dupke S., Carganico A., Tappe A., Wellmann E., Saquinavir (SQV) in geboosteten Doppel PI-Regimen - Analyse der AROMA-Kohorte mit und ohne optimiertes Hintergrundregime, European Journal of Medical Research, Vol. 12, Suppl. II, 88/2007
Henrik Ekberg, M.D., Ph.D., Helio Tedesco-Silva, M.D., Alper Demirbas, M.D., Štefan Vítko, M.D., Björn Nashan, M.D., Ph.D., Alp Gürkan, M.D., F.A.C.S., Raimund Margreiter, M.D., Christian Hugo, M.D., Josep M. Grinyó, M.D., Ulrich Frei, M.D., Yves Vanrenterghem, M.D., Ph.D., Pierre Daloze, M.D., and Philip F. Halloran, M.D., Ph.D., for the ELITE–Symphony Study; Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation, The new england journal of medicine, 2007;357:2562-75.